Cargando…

The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012–2019

BACKGROUND: Inappropriate empiric antimicrobial treatment (IET) contributes to worsened outcomes. While IET’s differential impact across types of nosocomial pneumonia (NP: non-ventilated [nvHABP], ventilated [vHABP] hospital-acquired and ventilator-associated [VABP] bacterial pneumonia) is establish...

Descripción completa

Detalles Bibliográficos
Autores principales: Zilberberg, Marya D., Nathanson, Brian H., Puzniak, Laura A., Dillon, Ryan J., Shorr, Andrew F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533487/
https://www.ncbi.nlm.nih.gov/pubmed/36199012
http://dx.doi.org/10.1186/s12879-022-07755-y
_version_ 1784802357047984128
author Zilberberg, Marya D.
Nathanson, Brian H.
Puzniak, Laura A.
Dillon, Ryan J.
Shorr, Andrew F.
author_facet Zilberberg, Marya D.
Nathanson, Brian H.
Puzniak, Laura A.
Dillon, Ryan J.
Shorr, Andrew F.
author_sort Zilberberg, Marya D.
collection PubMed
description BACKGROUND: Inappropriate empiric antimicrobial treatment (IET) contributes to worsened outcomes. While IET’s differential impact across types of nosocomial pneumonia (NP: non-ventilated [nvHABP], ventilated [vHABP] hospital-acquired and ventilator-associated [VABP] bacterial pneumonia) is established, its potential interaction with the bacterial etiology is less clear. METHODS: We conducted a multicenter retrospective cohort study in the Premier Healthcare Database using an administrative algorithm to identify NP. We paired respective pathogens with empiric treatments. Antimicrobial coverage was appropriate if a drug administered within 2 days of infection onset covered the recovered organism(s). All other treatment was IET. RESULTS: Among 17,819 patients with NP, 26.5% had nvHABP, 25.6% vHABP, and 47.9% VABP. Gram-negative (GN) organisms accounted for > 50% of all infections. GN pathogens were ~ 2 × as likely (7.4% vHABP to 10.7% nvHABP) to engender IET than Gram-positive (GP, 2.9% vHABP to 4.9% nvHABP) pathogens. Although rare (5.6% nvHABP to 8.3% VABP), GN + GP infections had the highest rates of IET (6.7% vHABP to 12.9% nvHABP). Carbapenem-resistant GNs were highly likely to receive IET (33.8% nvHABP to 40.2% VABP). Hospital mortality trended higher in the IET group, reaching statistical significance in GN + GP vHABP (47.8% IET vs. 29.3% non-IET, p = 0.016). 30-day readmission was more common with IET (16.0%) than non-IET (12.6%, p = 0.024) in GN VABP. Generally post-infection onset hospital length of stay and costs were higher with IET than non-IET. CONCLUSIONS: IET is ~ 2 × more common in GN than GP infections. Although the magnitude of its impact varies by NP type, IET contributes to worsened clinical and economic outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07755-y.
format Online
Article
Text
id pubmed-9533487
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95334872022-10-06 The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012–2019 Zilberberg, Marya D. Nathanson, Brian H. Puzniak, Laura A. Dillon, Ryan J. Shorr, Andrew F. BMC Infect Dis Research BACKGROUND: Inappropriate empiric antimicrobial treatment (IET) contributes to worsened outcomes. While IET’s differential impact across types of nosocomial pneumonia (NP: non-ventilated [nvHABP], ventilated [vHABP] hospital-acquired and ventilator-associated [VABP] bacterial pneumonia) is established, its potential interaction with the bacterial etiology is less clear. METHODS: We conducted a multicenter retrospective cohort study in the Premier Healthcare Database using an administrative algorithm to identify NP. We paired respective pathogens with empiric treatments. Antimicrobial coverage was appropriate if a drug administered within 2 days of infection onset covered the recovered organism(s). All other treatment was IET. RESULTS: Among 17,819 patients with NP, 26.5% had nvHABP, 25.6% vHABP, and 47.9% VABP. Gram-negative (GN) organisms accounted for > 50% of all infections. GN pathogens were ~ 2 × as likely (7.4% vHABP to 10.7% nvHABP) to engender IET than Gram-positive (GP, 2.9% vHABP to 4.9% nvHABP) pathogens. Although rare (5.6% nvHABP to 8.3% VABP), GN + GP infections had the highest rates of IET (6.7% vHABP to 12.9% nvHABP). Carbapenem-resistant GNs were highly likely to receive IET (33.8% nvHABP to 40.2% VABP). Hospital mortality trended higher in the IET group, reaching statistical significance in GN + GP vHABP (47.8% IET vs. 29.3% non-IET, p = 0.016). 30-day readmission was more common with IET (16.0%) than non-IET (12.6%, p = 0.024) in GN VABP. Generally post-infection onset hospital length of stay and costs were higher with IET than non-IET. CONCLUSIONS: IET is ~ 2 × more common in GN than GP infections. Although the magnitude of its impact varies by NP type, IET contributes to worsened clinical and economic outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07755-y. BioMed Central 2022-10-05 /pmc/articles/PMC9533487/ /pubmed/36199012 http://dx.doi.org/10.1186/s12879-022-07755-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zilberberg, Marya D.
Nathanson, Brian H.
Puzniak, Laura A.
Dillon, Ryan J.
Shorr, Andrew F.
The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012–2019
title The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012–2019
title_full The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012–2019
title_fullStr The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012–2019
title_full_unstemmed The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012–2019
title_short The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012–2019
title_sort risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvhabp), ventilated (vhabp) hospital-acquired and ventilator-associated (vabp) bacterial pneumonia in the us, 2012–2019
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533487/
https://www.ncbi.nlm.nih.gov/pubmed/36199012
http://dx.doi.org/10.1186/s12879-022-07755-y
work_keys_str_mv AT zilberbergmaryad theriskofinappropriateempirictreatmentanditsoutcomesbasedonpathogensinnonventilatednvhabpventilatedvhabphospitalacquiredandventilatorassociatedvabpbacterialpneumoniaintheus20122019
AT nathansonbrianh theriskofinappropriateempirictreatmentanditsoutcomesbasedonpathogensinnonventilatednvhabpventilatedvhabphospitalacquiredandventilatorassociatedvabpbacterialpneumoniaintheus20122019
AT puzniaklauraa theriskofinappropriateempirictreatmentanditsoutcomesbasedonpathogensinnonventilatednvhabpventilatedvhabphospitalacquiredandventilatorassociatedvabpbacterialpneumoniaintheus20122019
AT dillonryanj theriskofinappropriateempirictreatmentanditsoutcomesbasedonpathogensinnonventilatednvhabpventilatedvhabphospitalacquiredandventilatorassociatedvabpbacterialpneumoniaintheus20122019
AT shorrandrewf theriskofinappropriateempirictreatmentanditsoutcomesbasedonpathogensinnonventilatednvhabpventilatedvhabphospitalacquiredandventilatorassociatedvabpbacterialpneumoniaintheus20122019
AT zilberbergmaryad riskofinappropriateempirictreatmentanditsoutcomesbasedonpathogensinnonventilatednvhabpventilatedvhabphospitalacquiredandventilatorassociatedvabpbacterialpneumoniaintheus20122019
AT nathansonbrianh riskofinappropriateempirictreatmentanditsoutcomesbasedonpathogensinnonventilatednvhabpventilatedvhabphospitalacquiredandventilatorassociatedvabpbacterialpneumoniaintheus20122019
AT puzniaklauraa riskofinappropriateempirictreatmentanditsoutcomesbasedonpathogensinnonventilatednvhabpventilatedvhabphospitalacquiredandventilatorassociatedvabpbacterialpneumoniaintheus20122019
AT dillonryanj riskofinappropriateempirictreatmentanditsoutcomesbasedonpathogensinnonventilatednvhabpventilatedvhabphospitalacquiredandventilatorassociatedvabpbacterialpneumoniaintheus20122019
AT shorrandrewf riskofinappropriateempirictreatmentanditsoutcomesbasedonpathogensinnonventilatednvhabpventilatedvhabphospitalacquiredandventilatorassociatedvabpbacterialpneumoniaintheus20122019